Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity

Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity

Oncolytic viruses (OVs) encoding various transgenes are being evaluated for cancer immunotherapy. Diverse factors such as cytokines, immune checkpoint inhibitors, tumor-associated antigens, and T cell engagers have been exploited as transgenes. These modifications are primarily aimed to reverse the...

Full description

Bibliographic Details
Main Authors: Jun Xie, Shaowei Wang, Yunhong Zhong, Ming Gao, Xuezhang Tian, Liting Zhang, Dongli Pan, Qingsong Qin, Bing Wu, Ke Lan, Zhi-Jun Sun, Junjie Zhang
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Molecular Therapy: Oncolytics
Subjects:
oncolytic virus
HSV-1
GBP1
IpaH9.8
restriction factor
cancer treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770523000311

Similar Items

Similar Items